Cypress Capital Group Purchases 1,719 Shares of Solventum Co. (NYSE:SOLV)

Cypress Capital Group increased its position in Solventum Co. (NYSE:SOLV) by 9.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 20,706 shares of the company’s stock after buying an additional 1,719 shares during the period. Cypress Capital Group’s holdings in Solventum were worth $1,444,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Landscape Capital Management L.L.C. purchased a new position in shares of Solventum in the third quarter worth $227,000. Intech Investment Management LLC purchased a new position in shares of Solventum during the third quarter valued at about $317,000. Cornerstone Advisors LLC increased its holdings in shares of Solventum by 33.0% in the third quarter. Cornerstone Advisors LLC now owns 3,625 shares of the company’s stock worth $253,000 after purchasing an additional 900 shares during the last quarter. Ontario Teachers Pension Plan Board bought a new position in Solventum during the third quarter valued at approximately $1,742,000. Finally, First Horizon Advisors Inc. grew its holdings in Solventum by 42.6% during the 3rd quarter. First Horizon Advisors Inc. now owns 1,572 shares of the company’s stock valued at $110,000 after buying an additional 470 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Stifel Nicolaus began coverage on shares of Solventum in a research report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. Morgan Stanley boosted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Wells Fargo & Company cut their target price on Solventum from $69.00 to $64.00 and set an “equal weight” rating on the stock in a research report on Friday, August 9th. Wolfe Research began coverage on Solventum in a report on Thursday, September 26th. They set a “peer perform” rating on the stock. Finally, BTIG Research started coverage on shares of Solventum in a research note on Thursday, September 5th. They issued a “neutral” rating on the stock. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $68.00.

Solventum Price Performance

Shares of SOLV stock opened at $68.39 on Thursday. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05. The business’s fifty day simple moving average is $70.49 and its 200-day simple moving average is $62.26.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.